iRadimed Corporation, a leading provider of MRI-compatible medical device technologies, saw its stock decline sharply in Thursday's morning trading session after issuing its 2025 revenue guidance that fell short of Wall Street expectations.
The company reported strong fourth-quarter 2024 results, with earnings per share of $0.44 beating consensus estimates. However, iRadimed's full-year 2025 revenue guidance range of $78 million to $82 million missed the consensus forecast of $80.66 million, although its adjusted earnings per share guidance of $1.71 to $1.81 was in line with expectations.
Investors reacted negatively to the disappointing revenue outlook, sending iRadimed's shares plunging by 5.14% in the morning trading session. The company's management will likely face questions from analysts during the upcoming earnings call regarding the factors behind the weaker-than-expected revenue guidance and strategies to drive top-line growth in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.